Respiratory Syncytial Virus (RSV) News and Research

RSS
Respiratory syncytial virus (RSV) causes mild, cold-like symptoms in adults and older children. However, it can cause serious problems in young babies, including pneumonia and severe breathing problems. In rare cases it can lead to death. Premature babies and those with other health problems have the highest risk. A child with RSV may have a fever, stuffy nose, cough and trouble breathing. Tests can tell if your child has the virus.
National Jewish Health receives U.S. patent for POPG and related compounds

National Jewish Health receives U.S. patent for POPG and related compounds

Carbohydrate-rich diet during pregnancy may predict RSV severity in infants

Carbohydrate-rich diet during pregnancy may predict RSV severity in infants

Okairos to commence novel RSV vaccine Phase I clinical trial

Okairos to commence novel RSV vaccine Phase I clinical trial

GSU associate professor receives federal grant to bolster flu vaccine research

GSU associate professor receives federal grant to bolster flu vaccine research

Severe RSV disease may impair innate immune response in infants

Severe RSV disease may impair innate immune response in infants

Vaccinating families could protect young babies against RSV infection

Vaccinating families could protect young babies against RSV infection

Gene silencing technology used to fight RSV and influenza

Gene silencing technology used to fight RSV and influenza

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alverix receives FDA 510(k) clearance for new BD Veritor System kit

Alverix receives FDA 510(k) clearance for new BD Veritor System kit

Differences in viral illness patterns play a role in asthma development in urban, suburban children

Differences in viral illness patterns play a role in asthma development in urban, suburban children

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Boosting immune system can help reduce asthma attacks due to viral infections

Boosting immune system can help reduce asthma attacks due to viral infections

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

Positive data from Synairgen’s SNG001 Phase II trial on asthma

Positive data from Synairgen’s SNG001 Phase II trial on asthma

Needle-free vaccine shows promise against RSV in children

Needle-free vaccine shows promise against RSV in children

GenVec announces data from respiratory syncytial virus vaccine program

GenVec announces data from respiratory syncytial virus vaccine program